1. High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
    Ji-Youn Sung et al, 2022, Biomedicines CrossRef
  2. Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia
    Ni Putu Ayu Widiasari et al, 2023, Romanian Journal of Internal Medicine CrossRef
  3. Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
    Hiroshi Nokihara et al, 2022, BMC Cancer CrossRef
  4. Prognostic impact of pleural effusion in patients with malignancy: A systematic review and meta‐analysis
    Yuan Yang et al, 2022, Clinical and Translational Science CrossRef
  5. The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
    Ping-Chih Hsu et al, 2020, Biomedicines CrossRef
  6. The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
    Long Wang et al, 2021, Cancer Management and Research CrossRef
  7. Prognostic value of venous thromboembolism in patients with advanced pancreatic cancer: a systematic review and meta-analysis
    Kaifeng Su et al, 2024, Frontiers in Oncology CrossRef
  8. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
    Ping-Chih Hsu et al, 2019, International Journal of Molecular Sciences CrossRef
  9. Risk factors for rib metastases of lung cancer patients with high-uptake rib foci on 99Tcm-MDP SPECT/CT
    Yuanyuan YANG et al, 2024, The Quarterly Journal of Nuclear Medicine and Molecular Imaging CrossRef
  10. Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment
    Nan Sethakorn et al, 2022, Cancers CrossRef
  11. Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence
    Luyao Ao et al, 2022, Journal of Experimental & Clinical Cancer Research CrossRef